OPEN END TURBO OPTIONSSCHEIN LONG - UCB Stock

DE000GG4YL93

Real-time BOERSE MUENCHEN 14:25:08 2024-07-17 EDT
4.27 ^EUR	-2.06%

Current month	+9.27%
1 month	+10.38%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Chart OPEN END TURBO OPTIONSSCHEIN LONG - UCB

Latest news about UCB

UCB : spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)	06-28	PU
UCB : Financial Reporting Document	06-26	PU
UCB : Financial Reporting Document	06-26	PU
UCB : epilepsy drug BRIVIACT(brivaracetam) approved in Japan for treatment of focal onset seizures	06-26	PU

More news

Quotes 5-day view

Date	Price	Change
24-07-17	4.27	-2.06%
24-07-16	4.36	-2.90%
24-07-15	4.49	-0.88%
24-07-12	4.53	+0.67%
24-07-11	4.5	-2.39%

Real-time BOERSE MUENCHEN

Last update July 17, 2024 at 02:25 pm

More quotes

Static data

Product type	Certificat Turbo
Buy / Sell	CALL
Underlying	UCB
Issuer	Goldman Sachs
WKN	GG4YL9
ISIN	DE000GG4YL93
Date issued	2024-03-07
Strike	99.77 €
Maturity	Unlimited
Parity	10 : 1
Emission price	1.1 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.68 €
Lowest since issue	0.7 €

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

142.6 EUR

Average target price

140.5 EUR

Spread / Average Target

-1.47%

Consensus